Tuesday 03 March 2020

3 March 2020 - Pennsylvania, US-based preclinical CRO L2P Research LLC has acquired New York-based METIS Research Laboratories, adding to L2P's network 5,000 square-foot GLP compliant facility, the company said.

Terms of the transaction were not disclosed.

The facility is focussed on providing Radiobinding assays, preclinical toxicology and whole body autoradiograph for innovators of advanced biotherapeutics.

The combination of L2P Research with its team of professionals and METIS Laboratories provides the pharmaceutical and biotech world with a partner for start-to-end lead discovery services enabling scientists to improve their research productivity and effectiveness and getting them to reach their goals.

L2P Research, LLC is research organisation that provides integrated R and D support in all the key areas of Pharmaceutical development. With a large worldwide customer base, L2P provides a complete array of research services as required for Investigational New Drug Applications.

METIS Laboratories provides radiotracer services for pharma, biotech and academic organisations. METIS Laboratories employs one of the oldest methods used for the evaluation of drug molecules, the Gold Standard, which is radiometric analysis of lead compounds.

The offer standard and specialised services in the areas of radioligand binding assays, receptor occupancy determinations, autoradiography, Quantitative Whole-Body autoradiography, ADME-PK, small animal imaging and custom radiolabeling and synthesis.